ArticleArchives of academic emergency medicine2025
Incidence and Risk Factors of QT Prolongation and Torsades de Pointes following Intravenous Amiodarone Administration for Atrial Fibrillation: A Cohort Study.
Article in Archives of academic emergency medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Molecules to Machines: An Integrative Framework Linking Molecular Pathogenesis, Multi-Factorial Risk, Risk Stratification, Clinical Management, and Artificial Intelligence in QT Prolongation and Sudden Cardiac Death.Clinical cardiology · 2026Review
- Pharmacological Cardioversion with Cavutilide: Results of Restoration and Maintenance of Sinus Rhythm in Certain Categories of Patients with Atrial Fibrillation and Atrial Flutter.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Amiodarone has been reported to be associated with QTc interval prolongation and Torsades de pointes (TdP). This study aimed to assess the incidence and identify the risk factors of QTc prolongation and TdP associated with intravenous amiodarone therapy in patients diagnosed with atrial fibrillation (AF). Methods: A retrospective cohort study was conducted using electronic health records of Buddhachinaraj Hospital, a tertiary care center in Thailand, between January 2016 and September 2019. The study population comprised patients with AF who received intravenous amiodarone therapy. Incidence and associated risk factors for QTc interval prolongation and TdP were assessed using multivariable logistic regression analysis. Results: A total of 2,944 patients were included in the analysis. Among these, 49 cases of intravenous amiodarone-associated QTc interval prolongation or TdP were identified (33 (1.12%) and 16 (0.54%) cases, respectively), corresponding to an overall incidence of 1.66% Conclusion: Although the incidence of QTc interval prolongation and TdP related to intravenous amiodarone therapy in patients with AF was relatively low, the risk was significantly elevated in individuals with diabetes mellitus, a history of stroke, or concurrent use of antipsychotic or anticholinergic agents. These findings underscore the importance of vigilant risk assessment and monitoring in clinical practice to mitigate the potential for intravenous amiodarone-induced arrhythmic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.